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Abstract Male breast cancer (MBC) is a rare and poorly
known disease. Germ-line mutations of BRCA2 and, to
lesser extent, BRCA1 genes are the highest risk factors
associated with MBC. Interestingly, BRCA2 germ-line
rearrangements have been described in high-risk breast/
ovarian cancer families which included at least one MBC
case. Germ-line mutations of CHEK2 gene have been also
implicated in inherited MBC predisposition. The CHEK2
1100delC mutation has been shown to increase the risk of
breast cancer in men lacking BRCA1/BRCA2 mutations.
Intriguingly, two other CHEK2 mutations (IVS2+1G>A
and I157T) and a CHEK2 large genomic deletion (del9-10)
have been associated with an elevated risk for prostate
cancer. Here, we investigated the contribution of BRCA1,
BRCA2 and CHEK2 alterations to MBC predisposition in
Italy by analysing a large series of MBC cases, unselected
for breast cancer family history and all negative for
BRCA1/BRCA2 germ-line mutations. A total of 102 unre-
lated Italian MBC cases were screened for deletions/
duplications of BRCA1, BRCA2 and CHEK2 by multiplex
ligation-dependent probe amplification. No BRCA1,
BRCA2 and CHEK2 genomic rearrangements, including
the CHEK2 del9-10, were found in the series analysed.
Furthermore, none of the MBC cases and 263 male popu-
lation controls, also included in this study, carried the
CHEK2 1100delC, IVS2+1G>A and I157T common
mutations. Overall, our data suggest that screening of
BRCA1/2 rearrangements is not advantageous in MBC
cases not belonging to high-risk breast cancer families and
that common CHEK2 mutations play an irrelevant role in
MBC predisposition in Italy.
Keywords Male breast cancer  BRCA1  BRCA2 
CHEK2  Germ-line mutations 
Large genomic rearrangements  MLPA
Introduction
Male breast cancer (MBC) is a rare and still poorly known
disease compared to breast cancer (BC) in females [1]. In
Italy, it accounts for 0.2% of all cancers in males and
incidence rates, standardised on European population, are
approximately 1 new case · 100,000 male residents per
year [2]. A positive BC family history (FH) is associated
with increased MBC relative risk and about 20% of MBC
patients have a first-degree relative with the disease [3].
MBC predisposition can result from germ-line mutations in
BRCA2 (OMIM #6600185) and, at lower extent, in BRCA1
(OMIM #113705) genes. The frequency of BRCA1/BRCA2
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mutations ranges from 4 to 40% for BRCA2 and up to 4%
for BRCA1, being higher in the presence of founder effects
[3–5]. Although BRCA1/2 mutations are more frequent
among MBC cases with a positive BC-FH, they have also
been reported among FH-negative MBC patients [4, 6],
thus indicating that mutation screening is beneficial also
among MBC cases with no FH.
In addition to point mutations, BRCA1 and BRCA2
genes are also affected by large genomic rearrangements.
In the last few years, BRCA1/BRCA2 germ-line rear-
rangements have been extensively studied in high-risk
breast/ovarian cancer families [7, reviewed in 8, 9–19]. In
this familial setting the frequency of BRCA1 rearrange-
ments results higher compared to that observed for BRCA2
and the majority of BRCA2 rearrangements are identified in
high-risk families that included at least one MBC case [10,
12, 14, 19]. Thus, as for the association between MBC and
BRCA2 germ-line mutations, the presence of a male
affected by BC seems to be the strongest predictor for the
occurrence of BRCA2 rearrangements in high-risk families.
Germ-line BRCA2 rearrangements were observed in 7 to
13% of MBC families from different populations, includ-
ing French, Australian, Spanish and Portuguese [10, 14, 19,
20]. However, no BRCA1/BRCA2 rearrangements were
found in MBC families of German origin [16] and no
BRCA2 rearrangements were identified among Finnish
MBC cases unselected for BC-FH [21]. Difference in
genetic background and in case selection criteria, and the
relatively small number of MBC cases, thus far analysed,
could explain discrepancies in BRCA1/2 large genomic
rearrangements detection rate observed in various studies.
Considering that the overall frequency of BRCA2 rear-
rangements is rare, the relevance of MBC is an important
issue.
There is some evidence implicating the low-penetrance
BC susceptibility gene CHEK2 (OMIM #604373) in
inherited MBC predisposition. In particular, the CHEK2
1100delC mutation has been shown to confer approxi-
mately a 10-fold increase of BC risk in men lacking
BRCA1/BRCA2 mutations and it was estimated to account
for 9% of MBC cases [22]. Although this mutation has
been strongly associated with the increased MBC risk in
high-risk BC families this association is not so evident in
series of MBC cases unselected for FH [23–25]. Interest-
ingly, the contribution of the CHEK2 1100delC mutation to
BC predisposition varies by ethnic group and from country
to country. A decreased frequency of the 1100delC allele in
North to South orientation has been observed in Europe
[26, 27]. In Italy, this variant has been shown to play an
irrelevant role for BC risk in female [28], however, the role
of the CHEK2 1100delC has not been investigated in
Italian MBC. Two other common CHEK2 mutations, the
IVS2+1G>A and the I157T, have been associated with an
elevated risk for BC and prostate cancer [29–32]. The
contribution of these CHEK2 mutations to BC suscepti-
bility is still debated in females and no data are available in
males [33, 34]. Furthermore, a CHEK2 large genomic
deletion (del9-10), leading to loss of exons 9 and 10, has
been recently identified as a founder mutation in Czech,
Slovak and Polish populations and has been associated with
an increased risk of BC and prostate cancer [12, 35, 36]. No
data are currently available to what extent this deletion is
responsible for cancer burden in other populations.
In the present study, we evaluated the contribution of
BRCA1, BRCA2 and CHEK2 large genomic rearrange-
ments in inheritance of MBC predisposition in Italy by
assessing their prevalence in a large series of MBC cases
unselected for BC-FH and all negative for BRCA1 and
BRCA2 point mutations. A total of 102 unrelated Italian
MBC cases were included in this study and screened by
Multiplex Ligation-dependent Probe Amplification
(MLPA). To further investigate the role of CHEK2 in MBC
susceptibility, we also analysed the prevalence of the three
common CHEK2 mutations, the 1100delC, IVS2+1G>A
and I157T, in all MBC cases and in 263 healthy adult male
population controls included in this study.
Patients and methods
A total of 102 unrelated Italian MBC cases, all BRCA1/
BRCA2 mutation negative, were included in this study
irrespectively of breast/ovarian cancer FH. MBC cases
were identified at four centres in Italy: the CSPO-Scientific
Institute of Tuscany (Florence), the Cancer Genetic
Counselling Center, Department of Experimental Medicine
of the University ‘‘La Sapienza’’ (Rome), the Regional
Reference Centre for the Biomolecular Characterization
and Genetic Screening of Hereditary Tumors, University of
Palermo (Palermo) and the Clinical Experimental Oncol-
ogy Laboratory, National Cancer Institute (Bari). All MBC
patients signed informed consent form with description of
the study protocol, including the information about the
mutational analysis of the BRCA1/BRCA2 genes. Overall,
our conventional screening approaches included the anal-
ysis of the full coding sequence and intron/exon boundaries
of both BRCA1 and BRCA2 genes by combining PTT,
SSCP and direct sequencing [6, 18, 37]. For each study
participant we obtained information on his FH for cancer at
any sites, including all first- and second-degree relatives.
Procedures to maintain confidentiality for all the informa-
tion collected were strictly applied. A series of 263 healthy
adults males were also included in this study as represen-
tative of control population. All participants signed an
informed consent form and provided a blood sample. The
study was approved by local ethical committees. Genomic
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DNA of MBC patients and population controls was
extracted from peripheral blood lymphocytes by means of
standard phenol-chloroform extraction.
MLPA analysis
BRCA1, BRCA2 and CHEK2 deletions/duplications were
investigated by Multiplex Ligation-dependent Probe
Amplification (MLPA) using the SALSA MLPA KIT P002
BRCA1, which includes probes for each of the 24 exons of
BRCA1, and the SALSA MLPA KIT P045 BRCA2/
CHEK2, which includes probes for BRCA2 exons 1–4,
7–22, 24, 25, 27 and probes for promoter region located
about 2kb before CHEK2 exon 1 and for CHEK2 exon 9
(MCR Holland, Amsterdam, The Netherlands). MLPA
probes were hybridised to target sequences, ligated and
amplified in a PCR reaction using the GeneAmp PCR
System 9700 (Applied Biosystems, Warrington, UK)
thermal cycler system, as previously described [18].
Briefly, denatured genomic DNA was hybridised overnight
with the MLPA probes, PCR amplification of the ligation
products was carried out with FAM-labelled primers using
the alternative PCR protocol 2. Each PCR product, diluted
in GeneScan-Rox 500 size standards and deionized form-
amide, was run on an ABI 3100 Genetic Analyzer (Applied
Biosystem, Warrington, UK). Fragment analysis took
advantage of the Genescan 3.1 software (Applied Biosys-
tems, Foster City, CA, USA). For the statistical analysis we
transferred the size and the peak areas of each sample to an
Excel file and the peak areas of expected MLPA products
were evaluated by comparison with a normal control and
by cumulative comparison of all samples within the same
experiment. DNA samples showing probes with a dosage
value less than 0.7 or greater than 1.2 were tested again.
For quality control, samples with known BRCA1/BRCA2
rearrangements, kindly provided by Dr. Marco Montagna,
were included in every MLPA reaction. Putative BRCA1/2
rearrangements were analysed by performing reverse
transcriptase PCR (RT-PCR) and Real-Time quantitative
PCR (qPCR) approaches. RT-PCR analysis of the BRCA1/
BRCA2 transcript was carried out using Superscript II
(Invitrogen, Carlsbad, CA, USA) reverse transcriptase with
gene-specific primers for the cDNA. Total RNA extrac-
tions were carried out by using Trizol reagent from
peripheral blood leukocytes, as recommended by the
manufacturer (Invitrogen, Carlsbad, CA, USA). SYBR
green Real-Time qPCR was performed on a 7900 Real
Time thermocycler (Applied Biosystem, Warrington, UK),
as previously described [18]. Briefly, dilutions of a control
DNA were used to generate calibration curves for each
exon and, for each sample, the values obtained for each
BRCA1/BRCA2 exon investigated were normalized on
reference exon values. To exclude single base changes
impairing the ligation reaction, the MLPA probe ligation
sites were analysed by direct sequencing. Sequencing
reactions were performed using an ABI PRISM DyeDeoxy
Terminator Cycle Sequencing Kit and ABI 3100 Genetic
Analyzer (Applied Biosystems, Warrington, UK).
CHEK2 mutations analysis
The presence of the three common CHEK2 mutations, the
1100delC, IVS2+1G>A and I157T, was investigated in all
MBC cases and controls. MBC cases were screened for the
CHEK2 1100delC by using the SALSA MLPA KIT P045
BRCA2/CHEK2 which includes a specific probe for
CHEK2 exon 10 resulting in a 490 bp amplification prod-
uct in the presence of this mutation. Direct sequencing of
CHEK2 exon 10 was performed to screen controls and to
verify the MLPA results in a half of the MBCs (56 cases)
analysed. Because of the presence of several CHEK2-
related pseudogenes in the human genome, two primers
sets were specifically designed for nested-PCR. The
CHEK2 IVS2+1G>A and I157T (470 T>C) mutations,
located in intron 2 and exon 3, respectively, were analysed
by PCR-RFLP. A genomic region covering both CHEK2
intron 2 and exon 3, was amplified by PCR using muta-
genic primers to allow for a subsequent restriction enzyme
screening. The 194 bp amplification product is cleaved by
PstI (New England Biolabs, Beverly, MA) in the presence
of the I157T mutation, whereas for the IVS2+1G>A the
wild-type product is cleaved by ScrFI (New England Bi-
olabs, Beverly, MA). Primers sequences and amplification
conditions are available upon request.
Results
In order to evaluate the prevalence and the spectrum of
BRCA1 and BRCA2 genomic rearrangements in MBC, we
screened a series of 102 unrelated Italian MBC cases with
no detectable BRCA1/BRCA2 point mutations, by MLPA.
All MBC patients were included irrespectively of breast/
ovarian cancer FH. Among all cases, a positive FH of
breast-ovarian cancer in at least one first-degree relative
was reported in 25 of the 102 (24.5%) MBC patients
(Table 1). In particular, 10 (10/102, 9.8%) MBC cases
belonged to high-risk breast-ovarian cancer families with
two or more BC cases or additional high-risk features such
as early age at BC diagnosis (less than 40 years) or bilat-
eral BC (Table 1). Notably, one case belonged to MBC
family in which another MBC case was diagnosed at 56
years of age (Table 1). Overall, age at BC diagnosis ranged
between 24 and 90 years (median, 67 years). All 102 MBC
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cases analysed resulted negative for BRCA1 rearrange-
ments. One sample showed an abnormal BRCA2 MLPA
profile. Based on the reduced probes dosage (a dosage
quotient less than 0.6) a BRCA2 exon 10 deletion could be
suspected (Fig. 1a). This result was consistently replicated
in three independent experiments. To confirm this data by
using different techniques, we performed a qPCR assay
that we recently developed and successfully applied for
quantifying specific BRCA1 exons dosage [18]. Here, the
dosage of BRCA2 exon 10 region, normalized on reference
BRCA2 exon 25 values, was performed by means of qPCR
and no exon 10 loss was detected (data not shown). To
exclude the presence of sequence variants that could affect
the MLPA reaction, direct sequencing of a 139 bp PCR
fragment, encompassing the ligation site (nt 1376) of the
MLPA probe for BRCA2 exon 10, was performed. An
heterozygous A>T substitution at nt 1374, was identified in
the genomic DNA of the MBC case showing the altered
MLPA profile. This BRCA2 variant, 1374 A>T (K382N), is
not reported in the BIC database (http://research.nh-
gri.nih.gov/bic). Since it is located just 1 bp upstream the
ligation site, it may potentially affect the ligation reaction
at the exon 10 probe binding site and cause the altered
MLPA profile (Fig. 1b). Overall, no BRCA2 rearrange-
ments were found in the 102 MBC cases analysed. In this
study, we used the SALSA MLPA KIT P045 BRCA2/
Table 1 Distribution of the 102
unselected MBC cases analysed
according to breast/ovarian
cancer family history in first-
degree relatives
No. of subjects (%)
Total MBC patients 102
MBC cases with negative FH 77 (75.5%)
MBC cases with positive FH 25 (24.5%)
MBC cases with high-risk FH
Breast/Ovarian Cancer in 2 or more relatives 3
Early onset BC (<40 years) 4
Bilateral BC 2
MBC 1
Total 10 (9.8%)
Fig. 1 (a) Electropherograms
of BRCA2 MLPA analysis.
Comparison between a MBC
sample showing BRCA2 exon
10 signal reduction (top) and a
control sample (bottom).
Arrows indicate the BRCA2
exon 10 probe position. (b)
Graphic explicative model of
BRCA2 exon 10 signal
reduction. The presence of the
heterozygous germ-line BRCA2
1374 A>T substitution,
occurring near to the exon 10
probe binding site (underlined),
creates a mismatch (bold) and
affects the ligation reaction,
thus causing a reduction of
BRCA2 exon10 probe signal
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CHEK2 (MCR Holland, Amsterdam, The Netherlands).
Since this kit contains a control probe specific for the
CHEK2 1100delC mutation, it allows the screening of this
mutation simultaneously in the same MLPA experiments.
Thus, we examined the presence of the CHEK2 1100delC
mutation in all 102 MBC cases analysed by MLPA.
Moreover, 263 healthy adult male population controls were
screened for this mutation by direct sequencing. None of
the MBC cases and controls carried the CHEK2 1100delC
mutation. To further analyse the role of CHEK2 alterations
in MBC predisposition, we extended our screening to
include two other common CHEK2 mutations, the
IVS2+1G>A and the I157T (470 T>C). All 102 MBC cases
and 263 controls were genotyped for the presence of these
two mutations by PCR-RFLP. None of the MBC cases or
controls carried the CHEK2 IVS2+1G>A and I157T.
Finally, taking advantage of using the SALSA MLPA KIT
P045 BRCA2/CHEK2 we could also exclude the presence
of CHEK2 rearrangements, including the CHEK2 del9-10,
in all 102 MBC cases tested by MLPA.
Discussion
In this paper, we report the results of the first multi-centre
study performed to investigate the prevalence and the
spectrum of BRCA1 and BRCA2 genomic rearrangements
in Italian MBC cases. A large series of MBC patients,
unselected for breast/ovarian cancer FH and with no
detectable BRCA1/BRCA2 germ-line point mutations, was
analysed by MLPA. No BRCA1 and BRCA2 genomic
rearrangements were detected in the 102 MBC cases
analysed. Currently BRCA1/BRCA2 germ-line rearrange-
ments are investigated in high-risk breast/ovarian cancer
families and a higher frequency of BRCA1, compared to
BRCA2, rearrangements is reported in this familial setting
[7–18]. Interestingly, BRCA2 rearrangements seem to be
clustered to high-risk families with at least one MBC case
[14, 19, 20], thus indicating the relevance of MBC to select
families for BRCA genes rearrangements analysis. With
regard to MBC, the majority of the studies have analysed
relatively small number of MBC cases and have focused on
the screening of BRCA2 rearrangements in familial MBC
[10, 14, 19–21]. It is noteworthy that also a BRCA1 germ-
line rearrangement was found in a high-risk BC family that
included a case of MBC [12]. Considering that BRCA1/2
germ-line mutations can be also identified in MBC with no
BC-FH [4, 6], in the present study, we wanted to assess the
relevance of BRCA1 and BRCA2 rearrangements in unse-
lected MBCs by analysing a large series of MBC patients
included irrespectively of their breast/ovarian cancer FH.
Overall, in our series about 25% of MBC patients reported
a positive breast/ovarian cancer FH in at least one first-
degree relative and about 10% belonged to high-risk
breast-ovarian cancer families. Notably, the fraction of
MBC cases with BC-FH in our series was consistent with
the overall percentage of FH-positive MBCs reported in the
general population [3], thus indicating that our series is
representative of a standard MBC population. Taking into
account that BRCA2 rearrangements were found in about
10% of high-risk MBC families [10, 14, 19, 20] and that
our series included 10 MBC cases belonging to high-risk
families we could have expected to find no more than one
case with genomic rearrangements. Overall, our data
indicate that BRCA1/2 rearrangements are irrelevant in the
settings of a standard MBC population and suggest that the
screening for BRCA1/2 rearrangements is advantageous
only in the context of high-risk MBC families.
Here, we performed MLPA to search for BRCA1/2
genomic rearrangements. MLPA is a rapid, high sensitive
and cost-efficient technique useful to screen large genomic
rearrangements [reviewed in 8]. However, MLPA shows
some technical limitations since probes target only short
sequences in each exon and rearrangements involving other
portions could be lost. In our experience false-positive
alterations involving single exons were quite common and
were resolved by repeated testing or by adopting a multi-
step approach implying different PCR-based techniques. In
the MBC series screened in this study, a putative BRCA2
exon 10 deletion was shown to be due to the presence of a
novel BRCA2 sequence variant (BRCA2 1374A>T) located
at the binding sites for the exon 10 probe. A MLPA profile
suggestive of a deletion of the BRCA2 exon 9 was also
observed in a MBC carrier of the BRCA2 1003delA germ-
line mutation [6] because of the occurrence of this mutation
at the ligation site of the MLPA probe for the BRCA2 exon
9. Thus caution in interpreting data and multiple approa-
ches in validating positive testing results are needed in
BRCA1/2 MLPA screening.
We also investigated the contribution of CHEK2 muta-
tions on inherited MBC predisposition in Italy by screening
MBC cases and population controls for the presence of the
three common CHEK2 mutations (1100delC, IVS2+1G>A
and I157T). Since the SALSA MLPA KIT P045 BRCA2/
CHEK2, used in this study, contains a control probe spe-
cific for the CHEK2 1100delC mutation, it allowed us to
screen for this mutation all MBC cases in the context of
BRCA2 MLPA analysis. Very recently, the simultaneous
screening for the CHEK2 1100delC mutation and BRCA1/2
rearrangements by MLPA has been proposed as a useful
strategy in populations in which the CHEK2 mutation
shows a very low frequency [38]. In our study, none of the
102 MBC cases, analysed by MLPA, and none of the 263
healthy adult male population controls, screened by direct
sequencing, carried the CHEK2 1100delC mutation, thus
suggesting that this mutation is very infrequent in the
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Italian male population. Indeed, a decreased frequency of
the 1100delC allele in North to South orientation has been
observed in Europe [26, 27]. In Italy, this variant has been
reported to play an irrelevant role for BC risk in females
[28]. Here, we showed that the CHEK2 1100delC variant
does not play a relevant role also for BC risk in males.
Although this mutation has been strongly associated with
the increased MBC risk in high-risk BC families [22] this
association is not so evident in population-based MBC
series [23–25]. Our data are concordant to results obtained
in other unselected MBC series, including those from
Finland, USA, UK and Israel, in which it was reported that
the CHEK2 1100delC is unlikely to account for a signifi-
cant proportion of MBC cases [23–25]. To further inves-
tigate the role of CHEK2 in inherited MBC predisposition,
we genotyped all 102 MBC cases and 263 controls for two
other common CHEK2 mutations, the IVS2+1G>A and the
I157T. None of the MBC cases and controls carried these
mutations. The CHEK2 IVS2+1G>A and I157T were
previously associated with an elevated risk for female BC
and prostate cancer [29–32], however, this association is
still debated [33, 34]. Our results suggest that the CHEK2
IVS2+1G>A and I157T play an irrelevant role in MBC in
Italy. Taking advantage of using the SALSA MLPA KIT
P045 BRCA2/CHEK2, which contains a probe specific for
CHEK2 exon 9, we could also exclude the presence of the
CHEK2 del9-10 in all MBC cases screened by MLPA. This
large CHEK2 deletion was recently identified as founder
mutation in Czech, Slovak and Polish populations and
associated with an increased risk of female BC and prostate
cancer [12, 35, 36]. Here, we showed that the CHEK2 del9-
10 does not play a role in MBC predisposition in Italy. It
will be of interest to further investigate whether CHEK2
mutations can be associated with prostate cancer in Italian
male population and, on the other hand, to verify whether
they can be associated with MBC in other populations.
Overall, our data suggest that screening of large BRCA1/2
rearrangements is not likely to be recommended in MBC
cases not belonging to high-risk families as well as
screening of common CHEK2 mutations is not advanta-
geous in Italian MBC cases.
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